440 | GOLDILOX: FIRST EXPERIENCE OF TWO DOSING STRATEGIES OF PIRTOBRUTINIB AND GLOFITAMAB FOR MANTLE CELL LYMPHOMA PREVIOUSLY TREATED WITH COVALENT BTK INHIBITORS

Documenti analoghi

• 604 | POLATUZUMAB VEDOTIN AS AN EFFECTIVE SALVAGE THERAPY FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA RESISTANTANCE TO BTK AND BCL INHIBITORS
  di: P. Yang, et al.
  Pubblicazione: (2025)
• 219 | PATIENT REPORTED OUTCOMES FROM BRUIN CLL‐321: PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKi PRETREATED CLL/SLL
  di: P. Barr, et al.
  Pubblicazione: (2025)
• 136 | MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE‐RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE ECHO TRIAL
  di: P. L. Zinzani, et al.
  Pubblicazione: (2025)
• 811 | RAPID STEP‐UP DOSING SCHEDULE OF GLOFITAMAB IS SAFE AND EFFICACIOUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
  di: J. Yang, et al.
  Pubblicazione: (2025)
• 47 | IBRUTINIB AND RITUXIMAB IS SUPERIOR TO IMMUNOCHEMOTHERAPY IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA DESPITE LOWER RATES OF MRD NEGATIVITY
  di: D. Lewis, et al.
  Pubblicazione: (2025)